Abstract
Chimeric antigen receptors are composed of antibody variable domains specific for a cell surface antigen fused to intracellular T cell co-stimulatory and activation domains. When introduced into T cells, these chimeric receptors allow for the recognition and subsequent activation against a non-human leukocyte antigen (HLA) restricted tumor antigen. This recent seminal study, together with {1,2}, by Carl June and colleagues used chimeric antigen receptors in chronic lymphocytic leukemia with remarkable effect. However, it remains to been seen whether the successes in treating hematological cancers can be transferred to solid tumors, not least because of the suppressive tumor microenvironment against T cells found with many solid tumor types (e.g., upregulation of inhibitory receptors on T cells) {3}. This Recommendation is of an article referenced in an F1000 Faculty Review also written by Carolina Soto Chervin and Bruce Brockstein.